Homepage
Author:
Apotex Inc.
Posted Date:
May 1, 2026
Apotex becomes the first Canadian‑based pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic®
Apotex Inc.
May 1, 2026
Apotex Announces FDA Approval of Generic Infuvite® Pediatric Injection, Eligible for 180‑day CGT Exclusivity (Single‑Dose Vial), Complementing its Recent Approval of Generic Infuvite Adult Injection
Apotex Inc.
April 27, 2026
Apotex Announces Strategic Transaction with Cumberland Pharmaceuticals to Integrate their U.S. Branded Businesses
Apotex Inc.
April 23, 2026
Apotex Announces Strategic U.S. Sterile Filling Partnership with Halo Pharmaceuticals
Apotex Inc.
April 14, 2026
Apotex Announces FDA Approval of First Generic Infuvite® Adult Injection (Single Dose Vial and Pharmacy Bulk package) with 180‑Day CGT Exclusivity for the Pharmacy bulk package in Partnership with Orbicular and Gland Pharma
Apotex Inc.
April 14, 2026
Apotex Receives First U.S. FDA Tentative Approval for a Generic Version of Ozempic® (Semaglutide Injection) in Partnership with Orbicular
Apotex Inc.
April 10, 2026
Apotex Strengthens Osteoporosis Care in Canada with Health Canada’s Approval of DENOZA™, a Denosumab Biosimilar
Apotex Inc.
April 7, 2026
Apotex announces leadership changes
Apotex Inc.
March 30, 2026
Apotex Expands Canadian Ophthalmology Portfolio with Health Canada’s Approval of CLOBIVIS™ (Clobetasol Propionate Ophthalmic Suspension, 0.05%)
Apotex Inc.
March 25, 2026
Apotex licenses exclusive Canadian rights to testosterone replacement therapy Nebido® from Grünenthal
Apotex Inc.
February 13, 2026
1
2
Next
